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Background: Artemisinin (QHS) and its derivatives dihydroartemisinin (DHA), artemether and artesunate have
become the first-line anti-malarials in areas of multidrug resistance. Declining plasma concentrations during the
repeated dosing have been reported for QHS, artemether and less convincingly for artesunate (ARS). However,
there is limited information on whether the concentrations of their active metabolite DHA and its subsequent
metabolites increased after multiple drug administrations. This study was designed to evaluate the potential
auto-induction metabolism of DHA in animal species. The sex-specific effect on the pharmacokinetic profiles of
DHA and its metabolites was studied. The pharmacokinetics of ARS, the prodrug of DHA, and its phase I/II
metabolites were also investigated.
Methods: Two groups of rats received a single oral dose of DHA or ARS, and another two groups of rats were
given oral doses of DHA or ARS once daily for five consecutive days. Plasma samples were analyzed for DHA, ARS
and their phase I/II metabolites, using a validated liquid chromatography tandem mass spectrometric (LC-MS)
method.
Results: DHA, monohydroxylated DHA (M1) and the glucuronide of DHA (DHA-G) were detected in rat plasma after
oral administration of DHA or ARS. Neither DHA nor its metabolites (M1 and DHA-G) changed significantly (P > 0.05)
in AUC0-t after 5-day oral doses of DHA or ARS. Sex difference was observed for DHA and its metabolites (M1 and
DHA-G), whereas its prodrug ARS did not show similar characteristics for the corresponding metabolites (DHA, M1
and DHA-G).
Conclusions: The results gave the direct evidence for the absence of auto-induction of phase I and phase II
metabolism of DHA and ARS in rats. The sex effect existed for DHA but not for ARS, which could be caused by the
sex-specific differences in absorption of DHA.
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Dihydroartemisinin (DHA, Figure 1) is a semisynthetic
anti-malarial derivative of artemisinin (Qing-hao-su,
QHS). It is widely used currently in the clinic for the
treatment of uncomplicated, complicated, or severe
malarias, including multidrug-resistant falciparum mal-
aria [1]. Artemisinin-based combination therapy (ACT)
is the recommended treatment for uncomplicated Plas-
modium falciparum malaria by WHO, and DHA-* Correspondence: xingjie@sdu.edu.cn
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reproduction in any medium, provided the orpiperaquine (ArtekinW) has been proven to be a pro-
spective candidate for ACT [2]. DHA is also the com-
mon metabolite of its methyl ether (artemether) and
hemisuccinate ester artesunate (ARS), both of which are
used in the treatment of malaria [3,4]. ARS could be rap-
idly converted to DHA (t1/2, 2-3 min), which in turn was
eliminated from the systemic circulation with a t1/2 of
40-50 min [5]. Thus, most of the anti-malarial activity
resulting from ARS administration is thought to be at-
tributable to DHA. Thirteen phase I metabolites and
three phase II metabolites of DHA have been detected
in human liver microsomes and rat liver microsomes [6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and


































































Figure 1 Structures of dihydroartemisinin (DHA), artesunate (ARS), monohydroxylated DHA (M1), the glucuronide of DHA (DHA-G),
artemether, and artemisinin (QHS).
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via bile into intestines and approximately 89-95% dose
of all conjugates were accounted for in rat blood, urine
and faeces [7]. The phase II metabolite α-DHA-G is an
important metabolite of DHA in humans, and its forma-
tion is catalyzed by UGT1A9 and UGT2B7 [5]. More
importantly, the glucuronide adducts possess high-to-
moderate anti-malarial activity [8].
QHS and artemether exhibited obvious time-
dependent pharmacokinetics in humans, and their
plasma concentrations decreased after multiple oral
doses [9,10]. Induction of the CYP2B6 and CYP3A4,
which are involved in the metabolism of artemisinin, has
been implicated as the underlying mechanism of their
time dependent pharmacokinetics [11,12]. A 5-day mul-
tiple dosing study of ARS in patients showed less con-
vincing evidence, in which the plasma concentration of
DHA at 2 h after each oral dose showed a time-
dependent decline [13]. However, another study did not
show time-dependent pharmacokinetics of ARS and its
metabolite DHA in healthy subjects [14]. A pharmacoki-
netic study on DHA in patients showed no differencesin the concentrations of DHA within the first two days
of treatment, whereas significant lower AUC of DHA
was observed on the fifth day, which was implicated to
be the results of physiological changes and possible
auto-induction metabolism [15].
Although, the disposition of artemisinin drugs has
been well studied in rodents and humans, no direct evi-
dence was available for the increased concentrations of
phase I/II metabolites of DHA in blood circulation sys-
tem after repeated administrations, partly because of the
extensive metabolism of DHA and the unavailability of
standards. The analysis of phase I/II metabolites of DHA
will be important to understand the auto-induction of
these drugs, since DHA is the major active metabolite
of artemisinin drugs and a preliminary investigation of
DHA (as well as ARS) displayed less convincingly
time-dependent pharmacokinetics.
Moreover, sex-specific differences in pharmacokinetics
have been reported to have important clinical conse-
quences, and it could become a predominant determinant
of inter-individual differences in therapeutic responses
[16]. Some representative sex-specific differences exist in
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bolic and clearance processes, and involvement of sex
hormones (i.e.,oestrogen and testosterone) in the regula-
tion of some metabolic enzymes. Thus, studies of sex-
specific differences in pharmacokinetics of DHA and its
metabolites would be important to understand the
potential auto-induction metabolism of DHA. The phar-
macokinetic properties of DHA were found to be
affected by gender and body weight in malarial patients
[17], whereas the gender difference was not observed in
healthy volunteers [18].
Based on the metabolite identification of DHA, the
pharmacokinetic study of DHA and its phase I/II meta-
bolites in rats after a single and multiple oral doses of
DHA (as well as its prodrug ARS) was performed in the
present work. The sex difference was also evaluated.
Methods
Chemicals and reagents
DHA, ARS and QHS (as internal standard) were pro-
vided by Kunming Pharmaceutical Co. (purity >99.0%,
Yunnan, China). DHA glucuronide (DHA-G, Figure 1)
was synthesized, and its structure was confirmed by HR-
MS, 1H-NMR and 13C-NMR spectroscopy. Acetonitrile
and methanol (HPLC grade) were purchased from Fisher
Chemicals (Fairlawn, NJ, USA). All other chemicals used
were purchased from Sigma-Aldrich or Thermo Fisher
Scientific, and were of highest purity available.
Instrumentation
All LC-MS experiments were carried out on a Thermo
Electron LTQ-Orbitrap XL hybrid mass spectrometer
(ThermoFinnigan, Bremen, Germany) equipped with an
electrospray ionization interface. An Accela HPLC sys-
tem (ThermoElectron) was equipped with an autosam-
pler, a vacuum degasser unit, and a quaternary pump.
The mass spectrometer employing positive ionization
was calibrated using the manufacturer’s calibration stan-
dards mixture allowing for mass accuracies <5 ppm in
external calibration mode. The ionization voltage was
4.2 kV and the capillary temperature was set at 275°C.
Nitrogen was used as both the sheath gas (40 units) and
auxiliary gas (10 units). The full scan mode across an
m/z range that bracketed DHA and its potential phase
I/II metabolites was used. Extracted ion chromatograms
(EICs) of m/z 302.196 for DHA, m/z 318.191 for mono-
hydroxylated DHA (M1), m/z 478.228 for DHA-G, m/z
402.212 for ARS, and m/z 283.154 for QHS, the internal
standard, with a 10 ppm range centered on the exact
m/z value were generated for quantitation.
Chromatographic separation was achieved on a Luna
ODS C18 column (150×2.1 mm i.d., 5 μm; Phenomenex,
Torrance, CA) with a 4.0×3.0 mm i.d. SecurityGuard
C18 (5 μm) guard column (Phenomenex, Torrance, CA).The chromatography was performed at 22°C. The mo-
bile phase consisted of acetonitrile/methanol/5 mM
aqueous ammonium acetate containing 0.05% (v/v) for-
mic acid (55:30:15, v/v), delivered isocratically at a flow
rate of 0.35 mL/min for quantitation assays of ARS,
DHA and their metabolites. The autosampler was set
at 4°C.
Quantification of ARS, DHA and their metabolites in rat
plasma
Plasma samples were subjected to a protein precipitation
extraction process, which was performed on ice. A 25
μL aliquot of rat plasma was mixed with 100 μL of IS
(4 μM, prepared in methanol) and 5 μL of methanol.
The mixture was mixed and centrifuged at 3000 g for
10 min. Aliquots (20 μL) of the solution were injected
onto LC-MS analysis. For calibration preparation, 25 μL
of drug-free plasma was mixed with 5 μL of stock solu-
tion (ARS, DHA and DHA-G) and 100 μL of IS. This
mixture was treated as above. The calibration graph was
plotted by least-squares linear regression of the peak-
area ratios (ARS, DHA or DHA-G to internal standard)
against concentrations of ARS, DHA or DHA-G. Matrix
matched calibration standards were obtained with con-
centrations of 20-2000 nM for DHA-G and 10-1000 nM
for ARS and DHA in plasma. QC samples were obtained
with three concentration levels (40, 400 and 1600 nM
for DHA-G; 20, 200 and 800 nM for ARS and DHA) in
plasma. Plasma samples were diluted with blank plasma
and reanalyzed when the concentration of DHA was
higher than the upper limit of quantification.
Quantitative data of the monohydroxylated metabolite
of DHA (M1) was extracted based on the calibration
curve of DHA. In this study, the pharmacokinetic profile
of M1 in rats after a single oral dose of DHA or ARS
will be used to compare with that after a multiple oral
dose, in order to evaluate the auto-induction metabol-
ism. In this case, the response factor for M1 compared
with that of DHA was not considered.
Method validation
The method was evaluated through linearity, intra- and
inter-day precision and accuracy. The accuracy and pre-
cision of the method were assessed by determining QC
samples using six replicated preparations of plasma sam-
ples at three concentration levels (40, 400 and 1600 nM
for DHA-G; 20, 200 and 800 nM for ARS and DHA) on
three separate days. The LLOQ represents the lowest
concentration of the analyte over the linear range that
can be determined with acceptable precision and
accuracy.
Bench-top stability was assessed by leaving the QC
samples of two different concentrations (40 and 1600 nM
for DHA-G; 20 and 800 nM for ARS and DHA) on ice
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was assessed at 4°C for 8 hours.
Drug administration and sample collection
Wistar rats (230-250 g) were supplied by Laboratory
Animal Center of Shandong University (Grade II, Cer-
tificate No. SYXK 2003-0004). The experimental proto-
col was approved by the University Ethics Committee
and conformed to the “Principles of Laboratory Animal
Care” (NIH publication no. 85-23, revised 1985). RatsFigure 2 Representative full-scan chromatograms of (A) a blank rat p
dihydroartemisinin (DHA; 10 nM), artesunate (ARS; 10 nM), the glucu
plasma sample at 0.17 h after a single oral dose of DHA (10 mg/kg); a
ARS (10 mg/kg). I: ARS (m/z 402.2122); II: the glucuronide of DHA (m/
metabolite of DHA (M1; m/z 318.1911); V: IS (m/z 283.1540).were maintained at 22 ± 2 °C and 55 ± 5% relative hu-
midity on a 12 h light–dark cycle for at least 5 days be-
fore being used. Rats were fasted for 12 h before drug
administration and for a further 3 h after dosing. Water
was freely available for rats during experiments. A group
of male rats (n = 6) and a group of female rats (n = 6)
were given a single oral dose of DHA or ARS 10 mg/kg.
Another group of male rats (n = 6) and female rats
(n = 6) were orally given DHA or ARS 10 mg/kg once
daily for five consecutive days. DHA was suspended inlasma sample; (B) a blank rat plasma sample spiked with
ronide of DHA (DHA-G; 20 nM) and IS (QHS, 4 μM); (C) a rat
nd (D) a rat plasma sample at 0.17 h after a single oral dose of
z 478.2283); III: DHA (m/z 302.1962); IV: the monohydroxylated
Figure 3 Mean (+S.D.) plasma concentration-time profiles of dihydroartemisinin (DHA), the monohydroxylated DHA (M1) and the
glucuronide of DHA (DHA-G) in male (triangular points; S-M and M-M) and female (square points; S-F and M-F) rats (n = 6 each)
following a single oral administration (solid points) or five consecutive days of oral doses (open points) of DHA (10 mg/kg).
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bonate injection (5%, pH 8.9). After oral administra-
tion, blood samples of 150 μL were withdrawn from
the jugular vein before dosing and at 0.08, 0.17, 0.33,
0.5, 0.67, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0 and 5.0 h post-dos-
ing. All heparinized blood samples were centrifuged at
3,000 g for 15 min and plasma was obtained. All the
plasma samples were stored at -80°C and assayed
within one month.
Data processing
The peak plasma concentration (Cmax) and time-to-peak
concentration (Tmax) were obtained from experimental
observations. The other pharmacokinetic parameters
were analysed by noncompartmental model using the pro-
gram TOPFIT (version 2.0; Thomae GmbH, Germany).
The area under the plasma concentration-time curve
(AUCo-t) was calculated using the linear trapezoidal
rule to the last point. The mean residence time (MRT)Table 1 The main pharmacokinetic parameters of dihydroarte
G) after one-day and five-day oral administrations of DHA (10
AUC0-t (nmol⋅h⋅L
-1) Cmax (n
One-day DHA M 1110.35 ± 724.56† 2062.22
F 322.16± 159.67† 562.71
M1 M 1202.13± 418.50† 996.67
F 191.46 ± 189.95† 180.02
DHA-G M 855.69 ± 789.17† 1443.21
F 58.16 ± 40.88† 236.11
Five-day DHA M 1512.55 ± 950.76† 2605.58
F 212.63 ± 202.33† 378.05
M1 M 2034.92± 903.13† 1102.67
F 157.11 ± 249.88† 153.58
DHA-G M 907.28 ± 542.38† 1155.90
F 19.33 ± 15.27† 125.30
*: P < 0.05 (single dose compared with multiple dose); †: P < 0.05 (male rats comparwas obtained by dividing the area under the first
moment-time curve (AUMC0-t) by the area under the
curve (AUC0-t). Total oral body clearance (CL/F) was
calculated as dose/AUC0-t.
Results were expressed as mean ± SD. The two-tailed
t-test was used for independent sample comparison of
the parameters between the single dose and multiple
dose groups. The acceptable level of significance was
established at P < 0.05.
Results and discussion
Metabolite identification using LTQ/Orbitrap
Rat plasma samples of DHA were analysed by LC-HR/
MS, as illustrated in selected ion chromatograms of
DHA, its phase I metabolite (M1) and phase II metabol-
ite DHA-G (Figure 2). Based on the accurate MS and
MS/MS spectra, M1 was proposed to be monohydroxy-
lated DHA. Their proposed structures are shown in
Figure 1. The metabolic profile of ARS, the prodrug ofmisinin (DHA) and its phase I/II metabolites (M1 and DHA-
mg/kg) to male (M) and female (F) rats (mean ± s.d)
mol⋅L-1) Tmax (h) MRT (h) CL/F (L/min/kg)
± 1364.13† 0.3 (0.2-0.5) 0.6 ± 0.1 0.75 ± 0.45†
± 273.86† 0.3 (0.2-0.5) 0.6 ± 0.1 2.36 ± 1.40†
± 244.81† 0.4 (0.3-0.5)† 1.0 ± 0.1† 0.53 ± 0.14†
± 158.28† 0.5 (0.3-0.7)† 0.7 ± 0.1† 5.48 ± 3.98†
± 1222.24† 0.3 (0.2-0.5) 0.6 ± 0.2† 1.78 ± 1.98†
± 232.63† 0.2 (0.2-0.3) 0.3 ± 0.1† 10.43 ± 5.63*†
± 1677.94† 0.4 (0.2-0.7) 0.8 ± 0.3 0.72 ± 0.82†
± 289.44† 0.3 (0.2-0.3) 0.6 ± 0.1 4.43 ± 2.83†
± 478.42† 0.5 (0.3-0.7) 1.3 ± 0.2† 0.35 ± 0.19†
± 229.01† 0.6 (0.5-0.7) 0.7 ± 0.1† 8.77 ± 6.61†
± 609.47† 0.3 (0.2-0.7) 1.0 ± 0.6† 0.82 ± 0.39†
± 58.48† 0.2 (0.2-0.2) 0.2 ± 0.1† 20.49 ± 2.58†
ed with female rats).
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tion of phase I and II metabolites of DHA in vitro and
in vivo using LTQ/Orbitrap has been shown in detail in
a previous study [6]. In the present study, the pharmaco-
kinetics of DHA and its two metabolites (M1 and DHA-
G) in relatively high concentration level were studied.
LC-MS method
Under optimized HPLC conditions, DHA, ARS and
their phase I/II metabolites were eluted within 10 min
(Figure 2). Blank rat plasma from six lots showed no sig-
nificant interfering peaks at the retention times of each
analyte (Figure 2A). The calibration curves of ARS, DHA
and DHA-G were linear over the concentration range of
10-1000 nM, 10-1000 nM and 20-2000 nM, respectively,
in rat plasma with correlation coefficients r > 0.99 when
evaluated by weighed (1/x2) least-squares linear regres-
sion. The lower limits of quantification (LLOQ) of ARS,
DHA and DHA-G in rat plasma were established at 10,
10 and 20 nM, respectively (Figure 2B). The precision
and accuracy of this method indicate that all coefficients
of variation at each concentration level are below 15%.
Previous studies have shown that ARS and DHA are not
stable at room temperature [19], and plasma samplesFigure 4 Mean (+S.D.) plasma concentration-time profiles of artesuna
metabolite of DHA (M1) and the glucuronide of DHA (DHA-G) in male
and M-F) rats (n = 6 each) following a single oral administration (solid
ARS (10 mg/kg).were processed on ice and stored at low temperature in
the present study. There was no significant difference
(<15%) between the responses of standards at time zero
and after storage of plasma on ice for at least 2 hours in
terms of %CV for ARS (6.8%), DHA (3.8%) and DHA-G
(6.1%), indicating that they were stable under this condi-
tion. Processed samples were stable (%CV <15%) for at
least 8 hours in the autosampler tray.
The semi-quantitation of the monohydroxylated metab-
olite of DHA (M1) was performed in this study due to un-
availability of the standard. The pharmacokinetic profiles
of DHA and its metabolites in rats after a single oral dose
will be used to compare with that after a multiple oral
dose, in order to evaluate the auto-induction metabolism.
Based on past experience it is reasonable to expect that
M1 will exhibit similar ionization efficiency to the parent
molecule DHA in positive ion mode. In this case, the re-
sponse factor for M1 compared with that of DHA was not
considered, and quantitative data of M1 could be
extracted based on the calibration curve of DHA.
Pharmacokinetics of DHA and its phase I/II metabolites
After DHA was orally administered to rats, DHA and its
two major phase I (M1) and phase II (DHA-G)te (ARS), dihydroartemisinin (DHA), the monohydroxylated
(triangular points; S-M and M-M) and female (square points; S-F
points) or five consecutive days of oral doses (open points) of
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pathways are hydroxylation and glucuronidation. Their
mean plasma concentration-time profiles of DHA and
its phase I/II metabolites after oral dosing of DHA are
shown in Figure 3, and the pharmacokinetic parameters
are given in Table 1.
Oral doses of DHA (10 mg/kg) once daily for five
consecutive days did not result in a significant decrease
(P > 0.05) in AUC0-t, Cmax, Tmax, MRT, CL or Vz of
DHA in either male rats or female rats compared with
values obtained after a single oral dose. Similar to the
parent drug DHA, the phase I/II metabolites M1 and
DHA-G did not show time-dependent pharmacokine-
tics. In a previous study, there were no differences in
the concentrations of DHA in Vietnamese patients
within the first two days of treatment with DHA. The
pharmacokinetics of DHA in the acute phase, however,
was significantly different from that in the convalescent
phase of malaria, which suggested that the change in
pharmacokinetics of DHA is related to the physiological
change in malaria patients between the acute and con-
valescent phases of the disease [15]. There was a time-
dependent decrease of DHA plasma concentrations
after the same repeated doses of Artekin tablets (DHA-
piperaquine) in healthy subjects. The inconsistent
pharmacokinetics of DHA may be caused by different
formulations of DHA, the manufacturing process, dif-
ferent prescriptions and ethnicity.
It is well known that remarkable decline in plasma
drug concentration was observed after repeated oralTable 2 The main pharmacokinetic parameters of artesunate
DHA, M1 and DHA-G) after one-day and five-day oral adminis
rats (mean ± s.d)
AUC0-t (nmol⋅h⋅L
-1) Cmax (nm
One-day ARS M 169.45 ± 52.77 657.30 ±
F 149.86 ± 52.36 677.70 ±
DHA M 1470.64 ± 695.34 2139.18 ±
F 1357.65 ± 564.25 2867.33 ±
M1 M 208.79 ± 140.96 197.74 ±
F 280.05 ± 202.13 195.61 ±
DHA-G M 568.52 ± 442.13 925.92 ±
F 395.43 ± 129.49 964.72 ±
Five-day ARS M 188.03 ± 107.53 864.21 ±
F 179.43 ± 111.88 861.62 ±
DHA M 1171.60 ± 613.77 2531.74 ±
F 893.01 ± 468.66 2008.96 ±
M1 M 203.02 ± 226.62 219.10 ±
F 282.03 ± 170.42 216.74 ±
DHA-G M 1105.48 ± 986.09 2396.47 ±
F 406.74 ± 135.55 1025.37 ±
*: P < 0.05 (single dose compared with multiple dose); †: P < 0.05 (male rats compardosing of QHS in humans and laboratory animals [9,20].
Auto-induction metabolism was supposed to be the
underlying mechanism. The elimination of QHS drugs
was reported to be mediated primarily by CYP2B6 and
CYP3A4 [11,12]. Artemisinin anti-malarials moderately
affect cytochrome P450 enzyme activity in healthy
subjects, and the 1-hydroxymidazolam/midazolam 4-h
plasma concentration ratio (CYP3A activity) was
increased after 5-day treatment by QHS (2.66-fold),
artemether (1.54-fold) and slightly by DHA (1.25-fold)
[21]. In a population pharmacokinetics study, the activ-
ity of CYP2B6 was increased 79.7% by QHS and 19.9%
by DHA [11]. It was found that QHS could induce the
activity of CYP3A4 (Emax 3.5-fold and EC50 5.9 μM)
and CYP2B6 (Emax 1.9-fold and EC50 0.6 μM) in pri-
mary human hepatocytes, whereas DHA has a small
inductive potential [22]. QHS could activate nuclear
receptors PXR and CAR, and result in the induction
of the expression of CYP2B6, CYP3A4, and MDR1 in
primary human hepatocytes and in the human intes-
tinal cell line LS174T [23]. 50 μM artemether and
arteether activated hPXR and hCAR comparable to
100 μM QHS. In contrast, DHA did not significantly
activate hPXR. These previous reports showed that the
time-dependent pharmacokinetics and auto-induction
metabolism were different between artemisinin drugs.
Even though the auto-induction metabolism was con-
firmed for QHS, there was limited direct evidence on
whether the concentrations of DHA metabolites really
increased after multiple drug administrations. In the(ARS) and its phase I/II metabolites (dihydroartemisinin:
trations of ARS (10 mg/kg) to male (M) and female (F)
ol⋅L-1) Tmax (h) MRT (h) CL/F (L⋅min
-1⋅kg-1)
201.19 0.1 (0.1-0.2) 0.3 ± 0.1 2.78 ± 0.85
296.28 0.1 (0.1-0.2) 0.2 ± 0.04 3.15 ± 0.92
737.53 0.2 (0.2-0.3) 0.6 ± 0.1* 0.34 ± 0.13
982.21 0.3 (0.2-0.5) 0.6 ± 0.1 0.38 ± 0.18
135.08 0.5 (0.3-0.7)† 0.8 ± 0.2 2.74 ± 1.36
89.26 0.8 (0.5-1.0)*† 1.0 ± 0.2 2.55 ± 1.94
708.54 0.2 (0.2-0.3) 0.6 ± 0.2* 1.08 ± 0.54
293.54 0.2 (0.2-0.5) 0.4 ± 0.1 1.21 ± 0.43
444.42 0.1 (0.1-0.2) 0.2 ± 0.03 3.08 ± 1.78
580.92 0.1 (0.1-0.2) 0.2 ± 0.05 3.47 ± 2.07
1177.65 0.2 (0.2-0.3) 0.4 ± 0.1* 0.50 ± 0.32
925.29 0.3 (0.1-0.3) 0.4 ± 0.1 0.61 ± 0.32
195.25 0.4 (0.3-0.5) 0.6 ± 0.2† 9.50 ± 12.08
100.50 0.5 (0.3-0.7)* 0.9 ± 0.2† 2.11 ± 1.31
1827.67 0.2 (0.2-0.3) 0.4 ± 0.1* 0.82 ± 0.72
484.94 0.2 (0.1-0.3) 0.4 ± 0.2 1.20 ± 0.48
ed with female rats).
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not found for DHA and its major phase I/II metabo-
lites in rats, which was different from QHS [20].
On the other hand, there was significant difference
(P < 0.05) in AUC0-t and Cmax between male rats and
female rats in the present study. Male rats showed
higher concentration levels of DHA, M1 and DHA-G
with lower CL values than female rats after a single or
multiple oral doses. Simpson et al [17] suggested that
the pharmacokinetic properties of DHA were affected
only by gender and body weight in malarial patients.
However, another pharmacokinetic study showed that
there was no significant difference (P > 0.05) in gender,
which indicated that gender did not affect or change
the absorption, distribution and elimination of DHA in
healthy volunteers [18]. The inconsistent data resulting
from gender may be caused by a different metabolism
in healthy volunteers and malarial patients.
Although the validity of animal experiments to predict
efficacy and safety in human has been questioned, it is
generally believed that pharmacokinetic (PK) data can be
extrapolated to humans reasonably well, using the ap-
propriate PK principles [24]. Moreover, it is important to
realize that humans differ from animals with regard to
CYP isoform composition, expression and catalytic activ-
ities [24]. Interestingly, CYP2B has been found to be
sexual dimorphic in human and rat, and CYP3A forms
appear to be expressed in a sex-specific manner in rats
[24]. Additionally, sex differences in UGT activity are
reported relatively small and are confined to several
UGTs, including UGT2B15, which shows higher activity
in males, compared with females [25]. CYP2B, CYP3A
and UGT enzymes can be induced in both rodent and
non-rodent species, but these CYP or UGT isoforms
expressed in different species show different substrate
specifications. Thus, some caution should be applied
when extrapolating metabolism data of DHA from ani-
mal models to humans. Further assessment of induction
of CYP (particularly CYP2B and CYP3A) and UGT
enzymes involved in the metabolism of DHA, is required
to clarify the entire picture of species differences be-
tween humans and rats.
Pharmacokinetics of ARS and its phase I/II metabolites
After ARS was orally administered to rats, the parent
drug ARS, the active metabolite DHA and its subsequent
metabolites (M1 and DHA-G) could be detected
(Figure 2). Their mean plasma concentration-time pro-
files are shown in Figure 4, and the pharmacokinetic
parameters of ARS and its metabolites are presented
in Table 2.
Similar to DHA, oral doses of ARS (10 mg/kg) to male
or female rats once daily for five consecutive days did
not result in a significant change (P > 0.05) in AUC0-t orCmax of ARS and its major metabolites, including DHA
and its subsequent metabolites (M1 and DHA-G). Other
5-day oral dosing studies of ARS did not show time-
dependent pharmacokinetics of ARS and its metabolite
DHA in healthy subjects [14] and rats [26].
The effectiveness of ARS has been mostly attributed to
its rapid (t1/2, 2-3 min) and extensive hydrolysis to DHA
[5]. Unexpectedly, sex difference was not observed for
ARS and its metabolites in rats after a single oral dose of
ARS. The gender difference in AUC and Cmax by treat-
ment with DHA but not ARS indicated that the absorp-
tion process may play an important role. Even though
the species difference need to be carefully considered
when extrapolating metabolism data of DHA from ani-
mal models to humans, the effect of the formulation of
DHA tablets on the gender difference in pharmacokinet-
ics may still be clinically relevant.
Conclusions
The results gave the direct evidence for the absence of
auto-induction phase I/II metabolism of DHA and ARS.
The sex effect existed for DHA but not for ARS, which
could be caused by the sex-specific differences in ab-
sorption of DHA. From the point of auto-induction me-
tabolism, DHA seems to be a more promising anti-
malarials than its parent drug QHS and its derivative
artemether. The present study also showed the inductive
capacity is different among QHS drugs, which is import-
ant when selecting drugs to be used in anti-malarial
combination therapy such that the potential for drug-
drug interactions can be minimized.
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